Wang Lan, Lui Vivian Wai Yan
School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR 999077, China.
Cancers (Basel). 2020 Feb 12;12(2):426. doi: 10.3390/cancers12020426.
Anaplastic lymphoma kinase (ALK) is mostly known for its oncogenic role in several human cancers. Recent evidences clearly indicate new roles of ALK and its genetic aberrations (e.g. gene rearrangements and mutations) in immune evasion, innate and cell-mediated immunity. New ALK-related immunotherapy approaches are demonstrating both preclinical and clinical promises. Here, we provide a timely review on the most updated laboratory and patient-related findings on ALK and immunity, which would grant us important insights for the development of novel ALK immunotherapies for -altered cancers.
间变性淋巴瘤激酶（ALK）主要因其在几种人类癌症中的致癌作用而闻名。最近的证据清楚地表明了ALK及其基因畸变（如基因重排和突变）在免疫逃逸、先天免疫和细胞介导免疫中的新作用。新的与ALK相关的免疫治疗方法在临床前和临床方面都显示出前景。在此，我们及时综述了关于ALK与免疫的最新实验室和患者相关研究结果，这将为开发针对ALK改变的癌症的新型免疫疗法提供重要见解。
